---
title: "Citi Raises Zai Lab Limited  TP to USD45, Expects China Business to Stabilize in 2H26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295178255.md"
description: "Citi raised Zai Lab's target price to USD45, maintaining a 'Buy/High Risk' rating. The upgrade reflects confidence that China business will stabilize in H2 2026 and resume growth in 2027, supported by Q2 product revenue rising 11% QoQ to USD106 million. Key drivers include Tivdak's NMPA approval, partially offset by lower FY2026 KarXT revenue expectations and pricing pressure on Vyvgart due to insurance negotiations."
datetime: "2026-08-07T04:07:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295178255.md)
  - [en](https://longbridge.com/en/news/295178255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295178255.md)
generator: "portal-rs"
---

# Citi Raises Zai Lab Limited  TP to USD45, Expects China Business to Stabilize in 2H26

Citi said in a report that ZAI LAB (09688.HK) +2.220 (+15.279%) Short selling $33.58M; Ratio 40.908% 's product revenue for 2Q improved by about 11% QoQ to about USD106 million, in line with the broker's and market expectations, giving the broker greater confidence that its China business can stabilize in 2H26 and resume significant growth in 2027 in line with management guidance.

The broker said the focus is increasingly shifting to upcoming pipeline catalysts and continues to view zoci as the key value driver. The broker raised its US stock TP for Zai Lab Limited (ZLAB.US) from USD44 to USD45, factoring in the impact after Tivdak received approval from the National Medical Products Administration, partly offset by lower FY2026 KarXT revenue and assumed pricing pressure on Vyvgart due to national healthcare insurance negotiations for the subcutaneous formulation in 2027. Rating: "Buy/High Risk". (ha/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-06 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)
- [09688.HK](https://longbridge.com/en/quote/09688.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Is Positive ALKIVIA Myositis Data for VYVGART Hytrulo Altering The Investment Case For Zai Lab (ZLAB)?](https://longbridge.com/en/news/297443348.md)
- [Zai Lab’s Interim Results Show Lower Revenue but Rising R&D Investment](https://longbridge.com/en/news/296975726.md)
- [Citigroup announces Q3 2026 distribution of R$ 0.39 per unit, payable Sept. 3](https://longbridge.com/en/news/297699755.md)
- [Gaming and Leisure Properties declares Q3 2026 dividend of $0.82 per share](https://longbridge.com/en/news/297652371.md)
- [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**